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Background: Anti-SOX2 antibody responses are observed in about 10 to 20% of small cell lung cancer (SCLC)
patients. The aim of this study was to determine whether such responses reflect a particular pattern of SOX2
protein expression in the tumor and whether this pattern associates with clinical outcome.
Methods: Paraffin embedded tumor tissues, obtained from SCLC patients who had no evidence of paraneoplastic
autoimmune degeneration, were evaluated for SOX2 expression by immunohistochemistry for both intensity and
extent of staining. Sera from the same patients were tested for autologous antibodies against recombinant SOX2
by enzyme-linked immunosorbent assay (ELISA). Correlates between overall survival and various clinical parameters
including SOX2 staining and serology were determined.
Results: SOX2 protein expression was observed in tumor tissue in 89% of patients. Seventeen patients (29%) were
seropositive for SOX2 antibodies and, in contrast to SOX2 staining, the presence of antibody correlated with limited
disease stage (p = 0.05). SOX2 seropositivity showed a significant association with the intensity of SOX2 staining in
the tumor (p = 0.02) but not with the frequency of SOX2 expressing cells.
Conclusion: Anti-SOX2 antibodies associate with better prognosis (limited stage disease) while SOX2 protein
expression does not; similar to reports from some earlier studies. Our data provides an explanation for this
seemingly contrasting data for the first time as SOX2 antibodies can be observed in patients whose tumors contain
relatively few but strongly staining cells, thus supporting the possible presence of active immune-surveillance and
immune-editing targeting SOX2 protein in this tumor type.
Keywords: Tumor immunology, Cancer stem cells, Autologous antibody responses, Tumor antigens, Lung cancer,
Immunohistochemistry, Autologous antibodies, Cancer stem-cellsBackground
SRY-homology box group B1 genes (SOX1, SOX2, SOX3)
are known to function in neural plate, gut and lung devel-
opment [1,2]; and SOX2 has a role in maintaining the pluri-
potent stem cell phenotype [3]. In line with these facts,
SOX2 protein expression was shown to be an independent
marker for worse outcome in early stage lung adenocarcin-
oma [4] and to associate with tumor aggression and higher
grade in lung cancer [5]. Another study, however, correlated* Correspondence: agure@bilkent.edu.tr
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unless otherwise stated.SOX2 expression with lower grade and with better out-
come in squamous cell carcinoma of the lung [6], and a re-
cent study found a relation between SOX2 expression and
advanced disease, as well as worse overall survival in SCLC
[7]. These seemingly conflicting results could be due to
tumor type specific behavior of SOX2, or technical reasons
but they could also be due to presence of unacknowledged
confounding prognostic factors. We hypothesized that such
a factor could be the presence of an autologous immune re-
sponse against SOX2. Cancer patients can mount antibody
responses against a wide range of tumor antigens [8]. SOX
Group B1 proteins have been shown to elicit some of the
highest titered autologous anti-tumor antibody responsesLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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several studies showed no association between immune re-
sponses to SOX proteins and improved outcome [10,11],
although others did [12,13]. In this line, how anti-SOX2
antibody responses relate to SOX2 protein expression in
lung cancer remains unanswered. Since anti-SOX2 anti-
bodies are most frequently found in patients with small
cell carcinoma of the lung (SCLC), we asked if immunity
against SOX2 was related to its protein expression, and if
either related to clinical parameters determining outcome
in SCLC.
Methods
Patient and control population
The study cohort consisted of 59 patients with patho-
logically confirmed SCLC diagnosed between October
2007 and January 2009. All patients gave informed con-
sent and the study was approved by the ethical board of
the Atatürk Chest Diseases and Chest Surgery Education
and Research Hospital, Ankara, Turkey. All samples
were anonymized before analysis. None of the patients
had neurological symptoms or evidence of paraneoplas-
tic disease (PND) within the follow-up period. The clin-
ical data obtained from patients at the time of diagnosis
included age, gender, tumor stage, serum alkaline phos-
phatase (AP), and lactate dehydrogenase levels (LDH).
All patients received chemotherapy with or without
concurrent and sequential radiotherapy. Survival data
was available for all patients. Follow-up times ranged
from 0.2 to 44.7 months with a median of 8.68 months.
Sera from 157 age-matched healthy controls were
obtained after informed consent at the Capa Chest
Diseases and Chest Surgery Education and Research
Hospital of İstanbul, Turkey.
Enzyme-linked immunosorbent assay
Serum samples were obtained from all 59 patients, col-
lected at the time of diagnosis, between October 2007
and January 2009 and stored at −70°C. SOX2 and two
control proteins (EBV-p18 and DHFR) were expressed
and purified using the prokaryotic pQE expression sys-
tem (Qiagen Inc., Valencia, CA, USA). All constructs
contained cDNA corresponding to the full ORF of each
gene. Ninety-six well Immulon 4 HBX plates (Thermo
Scientific, Lafayette, CO, USA) were coated with 0.2 μg/
ml antigen at 4°C for 16 hours. Plates were blocked with
5 % non-fat milk in PBS. Patient sera were added to
plates at two dilutions (1:400, 1:1600) and incubated
for 2 h at 37°C and subsequently with goat anti-
human IgG - AP conjugate (Jackson Immunoresearch
Laboratories Inc., West Grove, PA, USA) at a dilution of
1:5000. The color reaction was read with an ELISA plate
reader (BioTek Instruments, Inc., Winooski, VT, USA).
Each experiment was repeated twice. A sample wasconsidered seropositive if the average of OD405 values
for the two dilutions for a given sample was above the
mean plus 2 standard deviation of that obtained for
healthy control serum (corresponding to an OD405
value of 1,799). Six control sera (3.8%) were seropositive
(Additional file 1: Figure S1). DHFR was used as nega-
tive and EBV p18 as positive controls. OD values ob-
tained for anti-p18 antibodies from patients and controls
were not statistically different.Western analysis of SOX2 seroreactivity
One hundred nanograms per well of recombinant
SOX2 protein was separated by 12% SDS-PAGE under
denaturing conditions and transferred to Immobilon-P
PVDF membranes (Milipore, St. Charles, MO, USA)
using the BioRad semi-dry transfer system. The mem-
branes were then blocked in 5% non-fat milk and
incubated with patient serum diluted at 1:3000 for
16 hours at 4°C, after which they were washed in TBS-
T and incubated with goat anti-human IgG (Fc-spe-
cific)-HRP (Sigma, St. Louis, MO, USA ) for 2 hours.
Immunoreactive protein was visualized using ECL-Plus
Western Blotting system (GE Healthcare, Buckinghamshire,
UK). Mouse anti-human SOX2 monoclonal antibody
(R&D Systems, Minneapolis, MN, USA) was used as a
positive control.Immunohistochemistry
Formalin-fixed paraffin embedded tumor tissues from all
patients, obtained at the time of diagnosis, were retro-
spectively evaluated by IHC. Fifty five of 59 tissues had
sufficient tumor tissue for a reliable evaluation. Tissues
were sectioned at 4 μm, placed on positively charged
slides and stained using a Ventana Benchmark LT
automatic immunostainer (Ventana Medical Systems,
Tuscon, AZ, USA). A range of dilutions of the primary
antibody as well as various incubation times and temper-
atures were tested for optimization. Monoclonal mouse
anti-human SOX2 primary antibody (MAB2018, R&D
Systems, Minneapolis, MN, USA) was used to stain sec-
tions at a 1:25 dilution for 40 minutes. The iViewT DAB
Detection Kit (Ventana Medical Systems, Tuscon, AZ,
USA), with standard CC1 pretreatment was used for de-
tection. IHC staining was estimated by microscopy as
the frequency (percentage) of stained cells as well as by
the intensity of staining (graded from 0 to 3). H-scores
were calculated as described previously [14]. All samples
were evaluated independently by two pathologists (SS
and FD). The NTERA-2 cell line was used as a positive
control and for optimization experiments. A normal tis-
sue (sausage) block was used as a negative control and
was included in every run.
Table 1 Clinical features and SOX2 antibody and protein














<70 14 3.97 0.47
≥70 44 8.68
U 1
Stage Limited 28 10.36 0.03
Extensive 27 7.34
U 1
SOX2 antibody <M + 2SD 42 8.68 0.3
≥ M+ 2SD 17 7.85
SOX2 IHC intensity** 0-1 25 7.39 0.98
2-3 30 10.65
SOX2 IHC frequency <5 % 16 25.87 0.12
≥5 % 39 7.39
SOX2 IHC frequency <20 % 24 7.4 0.11
≥20 % 31 7.86
SOX2 IHC frequency <40 % 29 7.39 0.43
≥40 % 26 9.68
*U: unknown. **Tumor tissue sections evaluations were available from
55 patients.
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Distribution of anti-SOX2 antibody or SOX2 staining in
each of age, sex, stage, AP and LDH categories were ex-
amined using frequency tables, and differences were
evaluated with two sided chi-square tests. Overall sur-
vival was defined as the time from diagnosis to death or
date of last follow-up. Data for patients that were alive
at the last contact were censored. SOX2 protein or anti-
body effects on survival were estimated by Kaplan-Meier
method and the log-rank test was used to compare sur-
vival across groups. All data were dichotomized as indi-
cated in the tables and analyzed as categorical variables.
All P values were two-sided. All analyses were per-
formed using GraphPad Prism version 6.00, (GraphPad
Software, San Diego California USA), or the Statistical
Package for the Social Sciences, version 19 (SPSS Inc.,
Chicago, IL).
Results
The clinical features of the 59 SCLC patients and their
association with overall survival are shown in Table 1.
Median age was 64 years (range, 44 to 85 years). All ex-
cept 6 patients were male. Cut-off values for AP and
LDH were 70 IU and 200 IU, respectively [15,16]. Fifty
one percent of the patients had limited stage disease at
the time of diagnosis. Limited disease stage was associ-
ated with longer overall survival (p = 0.03). Seventeen
of 59 patients (29%) had antibodies against SOX2
(Table 2), as determined by ELISA using recombinant
SOX2 protein, and confirmed by Western analysis
(Figure 1 and Additional file 1: Figure S1). We did not
observe an association of antibodies with overall sur-
vival (Additional file 1: Figure S2). However, SOX2
antibodies were more often present in serum from
patients with limited stage disease: while 12 of 28 pa-
tients with limited stage had SOX2 antibodies, only 5
patients with extensive disease were seropositive (p =
0.05) (Table 3). We could not find a statistically signifi-
cant correlation between SOX2 seropositivity and any
other clinical parameter. Positive staining by immuno-
histochemistry for SOX2 protein was observed in 42 of
55 tumors and was primarily nuclear and occasionally
cytoplasmic in character, ranging from very intense to
weak, with frequencies between 2% to 90% (Figure 2
and Table 2). Although in most cases only some cells
expressed SOX2, the intensity of staining for those
cells within a given tumor was always of similar inten-
sity. We found no statistically significant correlations
between frequency or intensity of SOX2 protein ex-
pression and any of the clinical features. We then
asked whether SOX2 antibodies correlated with SOX2
protein expression in tumor tissues. We found no sta-
tistically significant association between the frequency
of SOX2 staining and SOX2 antibody presence, whentumors were classified based on whether they con-
tained positively staining cells below and above a cut
off of 5, 20 or 40% of the total tissue (Table 1). When
evaluated for intensity of staining, all 13 patients with
no SOX2 expression in their tumors were found to be
seronegative for SOX2 antibodies. However, while only
2 of 12 patients with weak ("1") staining had antibodies
against SOX2, 14 of the 30 patients whose tumors con-
tained intensely staining cells ("2-3") were seropositive
for anti-SOX2 (p = 0.017); suggesting that strong SOX2
expression, even if focal, might suffice in inducing an
immune response against this antigen (Table 4). The
mean H-score for SOX2 seropositive tumors was larger
(156.8) than that for seronegatives (110.6), however,
the difference was not statistically significant (p = 0.25:
two sided t-test).
Table 2 SOX2 antibody and protein staining characteristics of SCLC patients
Patients SOX2 Ab (OD405) SOX2 staining frequency (%) SOX2 staining intensity H-score
AGH-KHA-04 4 2 2 6
AGH-KHA-56 3.93 2 3 8
AGH-KHA-46 3.87 UE* UE UE
AGH-KHA-38 3.84 95 3 380
AGH-KHA-74 3.78 100 3 400
AGH-KHA-71 3.77 5 2 15
AGH-KHA-48 3.66 30 2 90
AGH-KHA-62 3.62 45 2 135
AGH-KHA-73 3.06 10 3 40
AGH-KHA-87 2.93 5 2 15
AGH-KHA-59 2.83 90 3 360
AGH-KHA-77 2.74 30 2 90
AGH-KHA-96 2.7 60 1 120
AGH-KHA-39 2.42 90 3 360
AGH-KHA-37 1.98 10 1 20
AGH-KHA-21 1.97 50 2 150
AGH-KHA-32 1.93 80 3 320
AGH-KHA-93 1.78 2 1 4
AGH-KHA-76 1.68 0 0 0
AGH-KHA-81 1.28 5 1 10
AGH-KHA-28 1.23 0 0 0
AGH-KHA-90 1.2 80 2 240
AGH-KHA-17 1.2 0 0 0
AGH-KHA-66 1.19 0 0 0
AGH-KHA-75 1.18 25 1 50
AGH-KHA-80 1.15 UE UE UE
AGH-KHA-11 1.09 20 2 60
AGH-KHA-29 1.09 50 2 150
AGH-KHA-86 1.08 5 1 10
AGH-KHA-95 1.07 50 1 100
AGH-KHA-89 1.04 90 2 270
AGH-KHA-78 1.03 0 0 0
AGH-KHA-70 1.03 20 1 40
AGH-KHA-67 1.01 80 2 240
AGH-KHA-45 0.95 0 0 0
AGH-KHA-68 0.92 95 3 380
AGH-KHA-69 0.87 5 1 10
AGH-KHA-91 0.85 40 2 120
AGH-KHA-88 0.84 0 0 0
AGH-KHA-94 0.81 10 1 20
AGH-KHA-33 0.79 0 0 0
AGH-KHA-79 0.76 90 3 360
AGH-KHA-61 0.76 90 3 360
AGH-KHA-82 0.72 0 0 0
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Table 2 SOX2 antibody and protein staining characteristics of SCLC patients (Continued)
AGH-KHA-57 0.68 UE UE UE
AGH-KHA-53 0.65 70 2 210
AGH-KHA-55 0.65 70 2 210
AGH-KHA-15 0.64 0 0 0
AGH-KHA-40 0.64 60 2 180
AGH-KHA-64 0.63 70 2 210
AGH-KHA-72 0.61 40 1 80
AGH-KHA-24 0.55 90 3 360
AGH-KHA-51 0.55 60 3 240
AGH-KHA-43 0.54 0 0 0
AGH-KHA-12 0.52 UE UE UE
AGH-KHA-50 0.5 0 0 0
AGH-KHA-52 0.48 70 3 280
AGH-KHA-34 0.46 60 1 120
AGH-KHA-49 0.45 0 0 0
*UE: Unable to evaluate. Seropositive sera (OD405 > 1,799) are indicated in bold font.
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The illumination of the mechanisms underlying anti-
tumor immune responses is critical as such responses
can be ultimately boosted if their beneficial affect
can be proven. To our knowledge, this is the first
study where autologous anti-tumor antibody responses
against SOX2 have been correlated with tumor antigen
expression in SCLC. It is known that autologous anti-
bodies can be elicited against either upregulated, mu-
tated or foreign proteins [17]. SOX2 is amplified and
thus upregulated, but not mutated in SCLC [18]. In pa-
tients with monoclonal gammopathy of undetermined
significance (MGUS), anti-SOX2 T cell responses wereFigure 1 SOX2 Western results confirm ELISA data. Sera from patients
and those without antibodies (#70, 89, 11, 24, 79, 17) were analyzed by We
18kD), FB6 (a negative control, 35kD), and SOX2 (38kD), run in the first, sec
of SDS-PAGE analysis of the proteins used for Western is shown on the up
to premature translation termination.found to be directed against a very small percentage of
tumor cells which were of the clonogenic type [13].
In the same study, patients with anti-SOX2 T cells
showed significantly better overall survival. In contrast
to the case with MGUS, in SCLC, SOX2 immune re-
sponses, as measured by the presence of antibody, have
been observed to correlate with better outcome only in
one of the three cohorts studied so far [10-12]. We
believe there could be several explanations for this.
Firstly, as demonstrated in the MGUS study, anti-
SOX2 T-cell and antibody responses do not overlap
completely; therefore, if T-cell responses determine
outcome more so than antibodies, than this awaits towith anti-SOX2 antibodies according to ELISA (#71, 4, 87, 73, 77, 21)
stern blotting for reactivity against EBV p18 protein (positive control,
ond and third lanes of each gel, respectively. Coomassie blue staining
per right. Smaller molecular weight bands observed for SOX2 are due
Table 3 SOX2 antibody correlates with clinical stage
SOX2 Ab P (chi.sq.)
(−) (+)
Stage Limited 16 12 0.05
Extensive 22 5
Table 4 SOX2 antibody correlates with intensity of SOX2
protein expression
SOX2 Ab P (chi.sq.)
(−) (+)
SOX2 IHC intensity 0-1 23 2 0.017
2-3 16 14
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has shown an association between worse outcome, or
prognosis with SOX2 seropositivity. In contrast, SOX2
protein expression has been related to more aggressive
tumors in several studies [4,19-21] and the upregula-
tion of this gene is known to enhance tumor cell prolif-
eration [18]. In addition, SOX2 overexpression has
been shown to be essential for lung cancer stem cell
function [22,23]. It is possible that antibody responses
are associated with improved outcome, but given the
fact that SOX2 expression has the opposite effect, the
two cancel out each other. Larger and comprehensive
studies might further clarify these matters.
A very strong evidence that anti-tumor immune
responses can effectively eliminate selected cells in
humans comes from the observation that anti-tumor
responses against antigens expressed in tumors but
also in normal tissues, and in particular in Purkinje
cells of the cerebellum, are able to completely elimin-
ate these cells, without destroying surrounding tissues
[24]. The amount of antigen expressed by a given cell
has been shown to determine the type of T cell re-
sponse directed against it [25]. HER-2/neu specific im-
munity, for example, has been shown to depend on theFigure 2 SOX2 staining is heterogeneous. Tumors from three
seropositive (A-C; AGH-KHA-4, 71, and 21 respectively) and two
seronegative patients (D & E; AGH-KHA-72, and 89, respectively) are
shown. SOX2 staining is predominantly nuclear. In addition to tumor
cells, staining of bronchiolar epithelial cells was also observed (C).
See Table 2 for details of immunohistochemical evaluation and
SOX2 seropositivity testing results.antigens' expression level [26]. Therefore, it is possible
that only cells with intense SOX2 expression were able
to induce immune responses against them in the co-
hort we studied, potentially resulting in their loss,
similar to the case with Purkinje cells in patients with
anti-HuD antibodies. The fact that in our study SOX2
seropositive patients' tumors on occasion contained
very few cells could be reflecting the fact that such tu-
mors undergo immune-editing [27], and reach a state
of equilibrium between the tumor and the immune re-
sponse following a loss of most SOX2 expressing cells
[28]. Another explanation could be that those cells in
tumors from patients who are seropositive represent
clonogenic cells which elicit an immune response as
observed for MGUS patients [13]. In glioma the inten-
sity and not the frequency of SOX2 expression was
shown to be an indicator of a more stem-like pheno-
type [29]. On the other hand, the weak but diffuse
staining in a number of tumors we studied might re-
flect the presence of SOX2 expressing non-clonogenic
cells. This is likely as we and others have found mor-
phologically normal bronchial epithelium to be fre-
quently positive for SOX2 [30], and is also supported
by experiments showing that the transfection of a sec-
ond gene in addition to SOX2 is required for tumori-
genic transformation in some models [31,32].Conclusions
We report, for the first time, a relation between SOX2
protein expression characteristics and anti-SOX2 anti-
body responses in patients with SCLC. Although we find
no correlation between outcome or clinical measures
with frequency or intensity of SOX2 expression, we ob-
serve that SOX2 seropositivity associates with better
prognosis. Tumors from patients with SOX2 antibody
generally contain strongly staining cells, in contrast to
tumors from seronegative patients. This suggests that
the intensity of SOX2 expression might be critical in eli-
citing an anti-SOX2 immune response. The fact that
several tumors have very low numbers of such cells sug-
gests that SOX2 expressing cells could have been elimi-
nated over the course of disease, which is in support of
active tumor immune-surveillance and immune-editing
in these patients.
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Additional file 1: Figure S1. Scatter dot plot of SOX2 ELISA. The
median values for small cell lung cancer (SCLC) and healthy control sera
(CTR), as well as the cut-off for seropositivity (dotted line) are shown.
Figure S2. Kaplan-Meier analysis of patients stratified according to SOX2
seropositivity. Although seropositive patients show a trend for better
overall survival the difference, as calculated by the log-rank test,
is insignificant (p=0.3).
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